Vectibix to be sold in European Union

Vectibix® has been approved by the European Commission for marketing in all 27 European Union member states in combination with FOLFOX and FOLFIRI  to treat patients with metastatic colorectal cancer, which is predicted to affect 1.2 million people around the globe. The combination of drugs was shown to improve progression-free survival in two separate trials when compared to chemotherapy alone. Moreover, Vectibix® plus chemotherapy was higher than chemotherapy alone in the overall response rate. In 40 other countries, Vectibix® is already used as a monotherapy treatment. The drug has been in use in the United States since September 2006 as a monotherapy for patients with many different chemotherapy regimens.  

 

SOURCE: Amgen Press Release